Jump to content

Tedatioxetine

From Wikipedia, the free encyclopedia

Tedatioxetine
Clinical data
Other namesLu AA24530; Lu-AA-24530
ATC code
  • none
Legal status
Legal status
  • Investigational
Identifiers
  • 4-{2-[(4-methylphenyl)sulfanyl]phenyl}piperidine
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC18H21NS
Molar mass283.43 g·mol−1
3D model (JSmol)
  • CC(C=C1)=CC=C1SC2=C(C3CCNCC3)C=CC=C2
  • InChI=1S/C18H21NS/c1-14-6-8-16(9-7-14)20-18-5-3-2-4-17(18)15-10-12-19-13-11-15/h2-9,15,19H,10-13H2,1H3 checkY
  • Key:CVASBKDYSQKLSO-UHFFFAOYSA-N checkY
 X markNcheckY (what is this?)  (verify)

Tedatioxetine (developmental code name Lu AA24530) is an experimental antidepressant that was discovered by scientists at Lundbeck; in 2007 Lundbeck and Takeda entered into a partnership that included tedatioxetine but was focused on another, more advanced Lundbeck drug candidate, vortioxetine.[1]

As of 2009, it was in phase II clinical trials for major depressive disorder,[2]

but there have been no updates since then, and as of August 2013 it was no longer displayed on Lundbeck's product pipeline.[3][4]

On May 10, 2016, all work on tedatioxetine stopped.[5]

Pharmacology

[edit]

Pharmacokinetics

[edit]

CYP2D6 variability posed challenges for consistent dosing across populations, particularly for CYP2D6*17 and *41 carriers.[6]

Pharmacodynamics

[edit]

Synthesis

[edit]

A Chinese patent shows that there has been interest in this compound outside of Lundbeck.[7]

See also

[edit]

References

[edit]
  1. ↑ Beaulieu D (5 September 2007). "Lundbeck, Takeda enter strategic alliance for mood disorder, anxiety drugs]". First Word Pharma. Archived from the original on 10 October 2016. Retrieved 20 January 2016.
  2. ↑ "Lu AA24530 shows positive results in major depressive disorder phase II study". FierceBiotech. 2 July 2009. Archived from the original on 20 April 2012. Retrieved 9 March 2010.
  3. ↑ "Pipeline of Lundbeck". Archived from the original on 28 September 2012. Retrieved 25 August 2013.
  4. ↑ "Tedatioxetine". UK Medicines Information. Retrieved 20 January 2016.
  5. ↑ "Tedatioxetine". AdisInsight. Springer Nature Switzerland AG. Retrieved 2016-06-09.
  6. ↑ Frederiksen T, Areberg J, Schmidt E, Stage T, Brøsen K (Sep 2021). "Cytochrome P450 2D6 genotype–phenotype characterization through population pharmacokinetic modeling of tedatioxetine". ChemBioChem. 22 (17): 2711–2720. doi:10.1002/psp4.12663. PMC 8376138. PMID 34107164.
  7. ↑ WO 2015090160, Cao, Longji; Xin, Jianchuang & Yang, Xiangping, "Compound for preparing 4-(2-(4-methylphenylthio))phenylpiperidine, and preparation method and use thereof", published 2015-06-25, assigned to NHWA Pharma Corp.
[edit]